There are about 48,000 corneal transplants done each year in the U.S., compared to approximately 16,000 kidney transplants and 2,100 heart transplants[1] [2]. Out of the 48,000 corneal transplants done, 10 percent of them end up in rejection, largely due to poor medication compliance. This costs the health care system and puts undue strain on clinicians, patients and their families.
To develop a device based on nanophotonic technology that enables a quick and early diagnosis of different types of cancer –specifically breast, prostate, lung and colorectal– analysing only two or three drops of blood. This is the objective of SAPHELY, a European project funded by the EU's Horizon 2020 programme, led by the Valencia Nanophotonics Technology Center of the Universitat Politècnica de València. The SYM group of Centre for Molecular Recognition and Technological Development is also participating in the project as the second partner from the UPV.
Infection with highly contagious noroviruses, while not usually fatal, can lead to a slew of unpleasant symptoms such as excessive vomiting and diarrhea. Current treatment options are limited to rehydration of the patient. "Additionally, noroviruses come in a variety of constantly evolving strains. This makes the development of an effective vaccine to protect against infection, as well as antiviral therapy to combat already-existing infections, particularly challenging", says Dr. Grant Hansman, a virologist who leads the CHS Research Group on Noroviruses at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and Heidelberg University.
Every athlete, no matter what level they compete at, knows that training and practice weigh heavily on the outcome of each competition. But more importantly, are they aware of the rising incidence of incapacitating ‘superbugs’ that live in locker rooms, health clubs, gymnasiums and schools? Microorganisms such as E. coli, Staph, and MRSA can put a serious damper on a person’s ability to perform well in a sport, especially if they are not managed properly. These types of infections can and will spread to others, while possibly leading to season and/or career-ending injuries.
A new $10 million gift from Ronald and JoAnne Willens to Northwestern University’s International Institute for Nanotechnology (IIN) will establish an interdisciplinary research center that will use advances in nanotechnology to develop new cancer treatments. It will be one of the first centers of its kind in the country.
Aura Biosciences, a biotech company developing highly tumor-targeted breakthrough therapies for rare cancers, has secured a $21M Series B round of funding. The financing was led by Advent Life Sciences, with participation from new investors, Chiesi Ventures, Ysios Capital, and Alexandria Venture Investments.
Nanoparticles are extremely small particles that can be modified for a variety of uses in the medical field. For example, nanoparticles can be engineered to be able to transport medicines specifically to the disease site while not interfering with healthy body parts.
Cerulean Pharma Inc., a leader in Dynamic Tumor Targeting™, today announced it has signed a clinical research agreement with the GOG Foundation Inc. to conduct an open-label Phase 1b clinical trial of its lead product candidate, CRLX101, in combination with weekly paclitaxel in patients with relapsed ovarian cancer.
Thanks to the work of an interdisciplinary team of researchers at the Dartmouth Center of Nanotechnology Excellence, funded by the National Institutes of Health, the next-generation magnetic nanoparticles (MNPs) may soon be treating deep-seated and difficult-to-reach tumors within the human body.
Chemotherapy often shrinks tumors at first, but as cancer cells become resistant to drug treatment, tumors can grow back. A new nanodevice developed by MIT researchers can help overcome that by first blocking the gene that confers drug resistance, then launching a new chemotherapy attack against the disarmed tumors.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.